Buy Crypto Markets Spot FuturesBTC Earn Event Centre Rewards Hub

Coherus Oncology, Inc. (CHRS)

NASDAQ

$1,34

$-0,01

(-0,52%)

Pre-Market

Coherus Oncology, Inc. (CHRS) Live Price Chart

Last updated: ⁦2026-09-16 10:31:40⁩. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.

Summary

Coherus Oncology, Inc. (CHRS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1,34, with a market capitalisation of $220,94M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,09 to $2,62. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$220,94M
Open	$1,34
Day's High	$38,10
Day's Low	$0,45
Previous Close	$1,33
Volume	77,00
Average Volume	992,23K
P/E Ratio	--
52-Week High	$2,62
52-Week Low	$1,09
Dividend Yield	--
Earnings Date	--

Coherus Oncology, Inc. (CHRS) Pre-Market Stock Price

Coherus Oncology, Inc. (CHRS) is trading at $1,34 in pre-market trading as of 2026-09-16 09:03:00, up 0,38% ($0,00) from the previous close of $1,33

Pre-market trading shows how investors are pricing CHRS before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.

Coherus Oncology, Inc. (CHRS) 7-Day Stock Price Change

Over the past seven days, Coherus Oncology, Inc. (CHRS) moved from $1,42 to $1,34, representing a decline of 5,99% ($0,08).

The stock traded between $1,30 and $1,44 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.

The average daily volume was 754,51 thousand shares, up versus the previous seven-day period, indicating higher trading activity.

CHRS 52-Week Price Position

Position in Range: 16,1%

52W Low$1,09

52W High$2,62

CHRS is currently trading at $1,34, placing it 16,1% of the way from its 52-week low of $1,09 to its 52-week high of $2,62. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Coherus Oncology, Inc. (CHRS)?

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Coherus Oncology, Inc. Information

Industry	BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees	144
Exchange	NASDAQ
Company Website	https://www.coherus.com

How to Buy Coherus Oncology, Inc. (CHRS) Stock on MEXC

Eligible investors can buy real shares of Coherus Oncology, Inc. (CHRS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licenced broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for CHRS and Place Your Order

Open the RealStocks trading page and search for CHRS. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Coherus Oncology, Inc. (CHRS) stock price today?

Coherus Oncology, Inc. (CHRS) is currently trading at $ 1,34, up 0,38% ($0,00) from the previous close of $ 1,33. Intraday prices update in real time during regular trading hours.

2.Is CHRS stock going up or down today?

As of 2026-09-16 09:03:00, CHRS is trading at $ 1,34, up 0,38% ($0,00) from its previous close of $ 1,33. The stock has traded between $ 0,45 and $ 38,10 during today’s regular session. Past price movements do not guarantee future results.

3.What is CHRS pre-market price?

As of 2026-09-16 09:03:00, CHRS is trading at $ 1,34 in pre-market trading, up 0,38% ($0,00) from the previous close of $ 1,33. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is CHRS after-hours price?

As of 2026-09-16 09:03:00, CHRS is trading at $ 1,35 in after-hours trading, up 1,13% ($0,01) from the regular-session close of $ 1,33. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is CHRS stock trading now?

CHRS trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does CHRS sit relative to its 52-week high and low?

Over the past 52 weeks, CHRS has traded between a low of $ 1,09 and a high of $ 2,62. At $ 1,34, the stock is positioned 16,1% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is Coherus Oncology, Inc. in?

Coherus Oncology, Inc. (CHRS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is Coherus Oncology, Inc.'s market capitalisation and where is it listed?

Coherus Oncology, Inc. is listed on the NASDAQ exchange with a market capitalisation of $ 220,94M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is CHRS valued in terms of P/E ratio and EPS?

CHRS trades at a P/E ratio of --, based on trailing-twelve-month EPS of $ -0,86. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does Coherus Oncology, Inc. pay a dividend?

Coherus Oncology, Inc. pays an indicated annual cash dividend of $ 0,00 per share, with a current dividend yield of 0,00% based on the latest share price. Dividend policies are subject to change at the board's discretion.